<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03084991</url>
  </required_header>
  <id_info>
    <org_study_id>Harbin OCT-Registry</org_study_id>
    <nct_id>NCT03084991</nct_id>
  </id_info>
  <brief_title>OPTical Coherence Tomography IMAging in Patients With Acute myocardiaL Infarction (OPTIMAL)</brief_title>
  <acronym>OPTIMAL</acronym>
  <official_title>OPTical Coherence Tomography IMAging in Patients With Acute myocardiaL Infarction During Primary PCI (OPTIMAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the clinical outcomes, safety and&#xD;
      cost-effectiveness of intravascular OCT imaging in patients with acute myocardial infarction&#xD;
      undergoing percutaneous coronary intervention (PCI). About 4500 patients with acute&#xD;
      myocardial infarction (estimated 1500 with OCT guidance and 3000 without OCT guidance during&#xD;
      PCI）will be prospectively enrolled in 20 sites in China. The total duration of the study is&#xD;
      expected to be 5 years, 2 years for enrolment and 3 years for follow up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, non-randomized, observational registry study of patients&#xD;
      with acute myocardial infarction (AMI) that require catheterization. The purpose of this&#xD;
      registry is to investigate the clinical outcomes, safety and cost-effectiveness of&#xD;
      intravascular OCT imaging in patients with AMI undergoing PCI.The duration of the study is&#xD;
      expected to be 5 years, 2 years for enrolment and 3 years for total follow up.The clinical&#xD;
      study will be conducted in 20 centers in China.Approximately 4500 subjects (1500 with OCT&#xD;
      imaging and 3000 without OCT imaging) will be enrolled in this study.Subjects will be&#xD;
      followed up at 1, 3, 6, 12months and every 6 months afterwards up to 5 years. All subjects&#xD;
      need to be followed for at least 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major cardiovascular adverse events rate</measure>
    <time_frame>1 year</time_frame>
    <description>In patients treated conservatively, the safety objectives are to evaluate the occurrence of any adverse events in 1 year (re-infarction, re-hospitalization, revascularization by PCI or CABG, cardiac death, stoke, and major bleeding)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of procedural strategy changes during the primary PCI</measure>
    <time_frame>baseline</time_frame>
    <description>The rate of procedural strategy changes (thrombus aspiration or not, stenting or not, postdilation or not.) during the primary PCI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of procedural complications</measure>
    <time_frame>baseline</time_frame>
    <description>The incidence of procedural complications including coronary artery dissection, acute occlusion, thrombosis, re-infarction, emergent coronary artery bypass graft, bleeding, no/slow reflow, and death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the indience of different plaque characteristic in the setting of STEMI</measure>
    <time_frame>baseline</time_frame>
    <description>The incidence of plaque erosion, plaque rupture, calcified nodules, and other uncommon causes in the setting of STEMI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular adverse events rate</measure>
    <time_frame>2 and 3 year</time_frame>
    <description>The incidence of major adverse cardiovascular events (MACE) at 24 months and 36 months after index procedure.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">4500</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>OCT group</arm_group_label>
    <description>1500 AMI patients with OCT imaging guidance during PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAG group</arm_group_label>
    <description>3000 AMI patients without OCT imaging guidance during PPCI</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with AMI who undergo primary PCI.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting with:a.Symptoms of myocardial ischemia lasting for ≥ 30&#xD;
             minutes.b.Definite ECG changes indicating STEMI: ST elevation of greater than 0.1 mV&#xD;
             in two contiguous limb leads or 0.2 mV in two contiguous precordial leads, or presumed&#xD;
             new left bundle branch block. c. NSTEMI&#xD;
&#xD;
          -  Referred for primary PCI.&#xD;
&#xD;
          -  Are able to provide written Informed Consent prior to any study related procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who is unable to comply with the follow-up schedule.&#xD;
&#xD;
          -  Left main occlusion&#xD;
&#xD;
          -  Unable to restore TIMI flow grade III before stenting&#xD;
&#xD;
          -  Prior coronary artery bypass surgery (CABG)&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Patient who has any medical conditions that in the opinion of the investigator will&#xD;
             not be appropriate to participate in the study.&#xD;
&#xD;
          -  Patient has a life expectancy of less than 6 month due to any condition.&#xD;
&#xD;
          -  Age ≤ 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Yu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Affiliated Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Yu, MD,PhD</last_name>
    <phone>+86045186605180</phone>
    <email>yubodr@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haibo Jia, MD,PhD</last_name>
    <phone>+8615945685291</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing An Zhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zening Jin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Univerisity People'Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weimin Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lefeng Wang</last_name>
      <email>wlf311@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiang Xie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong general hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ning Tan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Guangxi medical university</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lang Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Hebei Meidical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xianghua Fu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daqing Oilfield General Hospital</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <zip>163001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Yu, MD,PhD</last_name>
      <phone>86-045186605180</phone>
      <email>yubodr@163.com</email>
    </contact>
    <investigator>
      <last_name>Bo Yu, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Zhengzhou medical university</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ling Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Genshan Ma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yanqing Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yang Zheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bin Liu</last_name>
      <email>liubin3333@vip.sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The third hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ping Yang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>the second affiliated hospital of Dalian medical university</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peng Qu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiao Tong University</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zuyi Yuan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Chest Hospital</name>
      <address>
        <city>Tianjing</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chunjie Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The General Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shaopeng Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yining Yang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>March 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>June 6, 2021</last_update_submitted>
  <last_update_submitted_qc>June 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Yu Bo</investigator_full_name>
    <investigator_title>Director,Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>NSTEMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

